Where does Onyx Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Onyx Therapeutics, Inc. ranks #12,151 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Onyx Therapeutics, Inc. hold?

Onyx Therapeutics, Inc. holds 25 US utility patents granted between 2015 and 2021, spanning 8 technology areas.

What is Onyx Therapeutics, Inc.'s Innovation Score?

Onyx Therapeutics, Inc. has an Innovation Score of 34.5 out of 100 (48th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Onyx Therapeutics, Inc. focus on?

Onyx Therapeutics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 22 patents, ranking #884 of 6,058 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Onyx Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Onyx Therapeutics, Inc.'s recent grant velocity is -61% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Onyx Therapeutics, Inc.'s patents?

Onyx Therapeutics, Inc.'s patents average 22.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Onyx Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Onyx Therapeutics, Inc.

USPTO PatentsView assignee record - 25 granted patents across 8 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Onyx ranks #12,151 of 49,997 tracked US assignees by granted-patent volume, with 25 patents across 8 technology areas.

#12,151
of 49,997 US assignees by volume: 48th percentile
by Innovation Score (34.5/100): 22.0
avg claims per patent: -61%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R12151 · US Corporation #12,151 · 25 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 25 grants
UPPER-Q #12,151/49,997
PHOTO-FINISH Obalon Therapeutics
CPC-NARROW A61P · 8 areas
INNOV-THIN 34.5/100
CLAIMS-DENSE 22.0 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -61% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Obalon Therapeutics, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Onyx’s 34.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.3 pts (33%) Velocity 0.0 pts (0%) Breadth 10.0 pts (29%) Claim depth 13.2 pts (38%)

Qualcomm Incorporated · highest

85
Latchways · near

34
Qcify · near

34
Cambridge Sound… · near

34
Onyx Therapeutics · this assignee

34
Signifier Medical · near

34
3D Lighting… · lowest

7

What this shows Onyx's Innovation Score is 34.5/100 (48th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Onyx?

Each dot is one of Onyx’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Onyx’s own 22.0 claims/patent is ABOVE the 17.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Onyx vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Onyx's grants concentrate

Onyx Therapeutics, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 88% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (7 grants) versus a trough of 1 in 2019. By volume, Onyx sits between Optimizely, Inc. and Outrider Technologies, Inc..

Optimizely

25
OPW Fueling Compo…

25
Obalon Therapeuti…

25
Oetiker Schweiz

25
Optodot

25
Oscor

25
Out Rage

25
Outrider

25
Onyx Therapeutics ◀

25

What this shows Onyx holds 25 patents at rank #12,151, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Onyx

By rank, the assignees closest to #12,151 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Onyx's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Onyx, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Onyx ranks #884 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (34 here).

Cambridge Sound Management, Inc. 34 Signifier Medical Technologies Limited 34 Latchways plc 34 Qcify, Inc. 34

Onyx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 48th percentile higher than 48% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Onyx Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	16.0%
2016	7	28.0%
2017	2	8.0%
2018	4	16.0%
2019	1	4.0%
2020	6	24.0%
2021	1	4.0%

Which technologies does Onyx Therapeutics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 22

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 21

C07K - Peptides 16

C07D - Heterocyclic Compounds 8

Y02A - Technologies FOR Adaptation TO Climate Change 3

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Onyx Therapeutics, Inc.'s patent record in context - here's where to go next.

Onyx Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 88% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #12,151 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Onyx Therapeutics, Inc. against Optimizely, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.